JW Pharmaceutical
001067
Company Profile
Business description
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
Contact
2477, Nambusunhwan-ro
Seocho-gu
KORT: +82 28406777
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,107
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.40 | 51.20 | 0.57% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,621.29 | 350.06 | 0.77% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,058.51 | 284.92 | -1.12% |
| NASDAQ | 21,707.69 | 209.97 | 0.98% |
| Nikkei 225 | 42,580.27 | 641.38 | 1.53% |
| NZX 50 Index | 13,133.20 | 58.39 | 0.45% |
| S&P 500 | 6,502.08 | 53.82 | 0.83% |
| S&P/ASX 200 | 8,826.50 | 59.20 | 0.68% |
| SSE Composite Index | 3,765.88 | 47.68 | -1.25% |